Delayed Clinical Response in Patients with Juvenile Idiopathic Arthritis Treated with Etanercept
M.H. Otten(Erasmus University Rotterdam), Lisette W. A. van Suijlekom‐Smit(Erasmus MC - Sophia Children’s Hospital), Nico Wulffraat(Utrecht University), R. ten Cate(Leiden University), Y. Koopman-Keemink(Juliana Kinderziekenhuis), Esther P A H Hoppenreijs(Radboud University Nijmegen), Femke H. M. Prince(Brigham and Women's Hospital), Wineke Armbrust, Simone Gorter(University Medical Center Groningen), Marion A. J. van Rossum(Reade), Sylvia Kamphuis(Erasmus MC), Marinka Twilt(University of Calgary)
Cited by 9
Related Papers
Mutations in RAB27A cause Griscelli syndrome associated with haemophagocytic syndrome
|Nature Genetics|2000|951
Anakinra as first‐line disease‐modifying therapy in systemic juvenile idiopathic arthritis: Report of forty‐six patients from an international multicenter series
|Arthritis & Rheumatism|2010|465
Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register
|Annals of the Rheumatic Diseases|2008|220
Sulfasalazine in the treatment of juvenile chronic arthritis: A randomized, double-blind, placebo-controlled, multicenter study
|Arthritis & Rheumatism|1998|217
Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study
|The Lancet Child & Adolescent Health|2019|214